Metformin reduced AR and ARv7 (an AR variant correlated with worse prognosis) expression, restoring miR26a-5p expression, which suppressed enhancer of zeste homolog 2 (EZH2), a catalyst of histone-3 lysine 27 trimethylation, that suppressed gene expression and has been correlated with tumor progression [60,61]. Here, EZH2 is linked to neoplasm.